Tools / Trials and research PIK3CD: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.
Drugs that act on it : 17 Approved : 5 In phases 1 to 3 : 12 Sponsors : 15 Who Is On It, and How Far Along Every drug ChEMBL records acting on PIK3CD, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved5 Copanlisib Copanlisib SponsorBayer ModalitySmall molecule ActionInhibitor Open trials15 Duvelisib Duvelisib SponsorSecura Bio ModalitySmall molecule ActionInhibitor Open trials15 Idelalisib Idelalisib SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials7 Leniolisib Leniolisib SponsorPharming Group ModalitySmall molecule ActionInhibitor Open trials4 Umbralisib Umbralisib SponsorTG Therapeutics ModalitySmall molecule ActionInhibitor Open trials4 Phase 32 Parsaclisib Parsaclisib SponsorIncyte Biosciences Japan GK ModalitySmall molecule ActionInhibitor Open trials4 Zandelisib Zandelisib SponsorMEI Pharma, Inc. ModalitySmall molecule ActionInhibitor Open trials0 Phase 28 Fimepinostat Fimepinostat SponsorCuris, Inc. ModalitySmall molecule ActionInhibitor Open trials1 Tenalisib Tenalisib SponsorRhizen Pharmaceuticals SA ModalitySmall molecule ActionInhibitor Open trials1 Acalisib Acalisib SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials0 AMG-319 AMG-319 SponsorAmgen ModalitySmall molecule ActionInhibitor Open trials0 INCB-40093 INCB-40093 SponsorIncyte ModalityOther ActionInhibitor Open trials0 Nemiralisib Nemiralisib SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 Seletalisib Seletalisib SponsorUCB Celltech ModalitySmall molecule ActionInhibitor Open trials0 TG100-115 TG100-115 SponsorTargeGen ModalitySmall molecule ActionInhibitor Open trials0 Phase 12 AZD-8186 AZD-8186 SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 CAL-263 CAL-263 SponsorGilead Sciences ModalityOther ActionInhibitor Open trials0
Modalities Modalities Share Copy link Download image (PNG)Drugs on this target by ChEMBL molecule type.
Small molecule 15 88%Small molecule Count15 Share88% Other 2 12%Other Count2 Share12%
The Landscape Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase p110-delta subunit inhibitor.
Open Trials The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 37 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib Phase 1 Not yet recruiting SecuraBio 2026-07-20 Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas Duvelisib Phase 2 Recruiting City of Hope Medical Center 2025-12-19 A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Idelalisib Phase 4 Recruiting Eli Lilly and Company 2025-10-20 A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia Parsaclisib — Not yet recruiting Peking Union Medical College Hospital 2025-09-02 A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) Idelalisib Phase 3 Recruiting Dizal Pharmaceuticals 2025-08-24 A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) Duvelisib Phase 1 Recruiting Memorial Sloan Kettering Cancer Center 2025-06-03 Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation Leniolisib Phase 2 Active, not recruiting Pharming Technologies B.V. 2025-05-25 A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Idelalisib Phase 3 Recruiting BeOne Medicines 2025-02-26 Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib Phase 1 / Phase 2 Recruiting Jonsson Comprehensive Cancer Center 2025-02-06 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis Idelalisib Phase 2 Active, not recruiting Calluna Pharma AS 2024-12-17 New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome Leniolisib — Recruiting Assistance Publique - Hôpitaux de Paris 2024-11-19 PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas Duvelisib Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China 2024-07-31 A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib Phase 3 Recruiting SecuraBio 2024-07-26 Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) Copanlisib Phase 2 Active, not recruiting National Cancer Institute (NCI) 2024-05-06 Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) Copanlisib Phase 2 Active, not recruiting National Cancer Institute (NCI) 2024-04-11 Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) Tenalisib Phase 2 Recruiting Rhizen Pharmaceuticals SA 2024-01-03 Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) Duvelisib Phase 2 Recruiting Liling Zhang 2023-08-04 Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Fimepinostat Phase 2 Recruiting University of California, Los Angeles 2023-08-02 (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) Duvelisib — Not yet recruiting Ruijin Hospital 2023-06-28 Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Idelalisib Phase 2 Recruiting Oslo University Hospital 2023-02-13 Pediatric Patients Aged 1 to 6 Years With APDS Leniolisib Phase 3 Active, not recruiting Pharming Technologies B.V. 2023-01-20 Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) Copanlisib Phase 2 Active, not recruiting National Cancer Institute (NCI) 2022-08-08 Pediatric Patients Aged 4 to 11 Years With APDS Leniolisib Phase 3 Active, not recruiting Pharming Technologies B.V. 2022-06-30 Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Copanlisib Phase 1 / Phase 2 Active, not recruiting City of Hope Medical Center 2021-06-25 Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma Umbralisib Phase 2 Active, not recruiting City of Hope Medical Center 2021-03-05 Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Idelalisib Phase 3 Active, not recruiting Loxo Oncology, Inc. 2020-12-14 To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) Parsaclisib Phase 1 / Phase 2 Active, not recruiting Incyte Biosciences Japan GK 2020-12-09 Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Umbralisib Phase 2 Active, not recruiting Jennifer R. Brown, MD, PhD 2020-11-12 Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib Phase 1 / Phase 2 Active, not recruiting Dana-Farber Cancer Institute 2020-10-01 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Parsaclisib Phase 2 Active, not recruiting Incyte Corporation 2020-08-12 Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Copanlisib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) 2020-04-15 Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Parsaclisib Phase 1 Active, not recruiting Mayo Clinic 2020-03-27 Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Copanlisib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) 2020-03-23 A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Copanlisib Phase 1 / Phase 2 Active, not recruiting Brown University 2020-02-05 Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Umbralisib Phase 1 Active, not recruiting University of Chicago 2017-09-14 Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Umbralisib Phase 2 Active, not recruiting National Cancer Institute (NCI) 2017-09-01 A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Idelalisib Phase 3 Active, not recruiting Acerta Pharma BV 2016-11-22
Show all 37Diseases Most Associated With It Open Targets association score, 0 to 1; all associations
Activated PI3K-delta syndrome 0.76
Immunodeficiency 14b, autosomal recessive 0.69
Combined immunodeficiency with faciooculoskeletal anomalies 0.61
Neoplasm 0.58
Neoplasm of mature B-cells 0.53
Marginal zone lymphoma 0.52
Combined immunodeficiency 0.46
Inborn error of immunity 0.45
Genes and Related Targets Complexes and families that share a gene with this target
Genes PIK3CD Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3130 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-18. Gene name, function (UniProt O00329 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets